INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

About this update from Inovio Pharmaceuticals, Inc.

[{"type":"list","items":[{"val":[{"type":"text","content":"Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026 ","length":307,"tagName":"p"}]},{"val":[{"type":"text","content":"INO-3107 immunological and long-term clinical and safety data published in Nature Communications and The Laryngoscope ","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"Advanced promising next-generation DNA medicine technology:","length":59,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Phase 1 proof-of-concept trial of DNA-encoded Monoclonal Antibodies (DMAbs) published in Nature Medicine","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Promising preclinical data on novel DNA-encoded protein (DPROT) technology presented at the World Federation of Hemophilia Global Forum","length":135,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":239,"olType":false}]},{"val":[{"type":"text","content":"Announced clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored trial","length":228,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":950,"olType":false},{"type":"text","content":"PLYMOUTH MEETING, Pa., March 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the fourth quarter and full year ended December 31, 2025 and provided an update on recent company developments.","length":402,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/INOVIO Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":129,"url":"https://media.zenfs.com/en/prnewswire.com/02f6eff2e3f0f811a2f544c30d57cb0d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Yd1bAc6HmDvRUbv9UGxnLw--/YXBwaWQ9aGl...

More updates from Inovio Pharmaceuticals, Inc.